Skip to contentN
Nautilus Biotechnology, Inc.
N
NAUTNautilus Biotechnology, Inc. Q2 2026 · 10-Q
Revenue$190.00K$190.00K— vs Q2 2025 Net Income-$14.47M-$14.47MN/M vs Q2 2025 EPS Diluted-$0.11-$0.11N/M vs Q2 2025 Operating Cash Flowderived-$13,726,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
Free Cash Flowderived-$14,180,000N/M ended Jun 30, 2026 · filed Jul 28, 2026 · 28 d after period end